Publications
Detailed Information
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Chie, Eui Kyu | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Ha, Sung Whan | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2009-09-22T13:19:34Z | - |
dc.date.available | 2009-09-22T13:19:34Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2007-04-12 | - |
dc.identifier.citation | BMC Cancer, Vol.7, p. 63 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 95291 | - |
dc.identifier.uri | https://hdl.handle.net/10371/9683 | - |
dc.description.abstract | Background: Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the identical adjuvant therapy at a single institution. Methods: A cohort of 151 curatively resected stage III breast cancer patients ( M: F = 3: 148, median age 46 years) who had 4 or more positive lymph nodes and received doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) as adjuvant chemotherapy was analyzed for clinico-pathologic characteristics including disease-free survival (DFS) and overall survival ( OS). Patients with positive ER and/or PR expression received 5 years of tamoxifen following AC/T. The protein expressions of biomarkers were assessed immunohistochemically. Results: The median follow-up duration was 36 months, and 37 patients (24.5%) experienced a recurrence. Univariate analyses indicated that the tumor size ( P = 0.038) and the number of involved lymph nodes ( P < 0.001) significantly affected the recurrences. However, the type of surgery, the histology, histologic grade, the presence of endolymphatic emboli, and a close resection margin did not. Moreover, ER positivity ( P = 0.013), bcl-2 positivity ( P = 0.002) and low p53 expression ( P = 0.032) were found to be significantly associated with a prolonged DFS. Furthermore, multivariate analysis identified 10 or more involved lymph nodes (HR 7.366; P < 0.001), negative bcl-2 expression ( HR 2.895; P = 0.030), and c-erbB2 over-expression ( HR 3.535; P = 0.001) as independent indicators of poorer DFS. In addition, bcl-2 expression was found to be significantly correlated with the expressions of ER and PR, and inversely correlated with the expressions of p53, c-erbB2 and Ki-67. Patients with bcl-2 expression had a significantly longer DFS than those without, even in the ER (+) subgroup. Moreover, OS was significantly affected by ER, bcl-2 and c-erbB2. Conclusion: Bcl-2 is an independent prognostic factor of DFS in curatively resected stage III breast cancer patients and appears to be a useful prognostic factor in combination with c-erbB2 and the number of involved lymph nodes. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | BioMed Central | - |
dc.title | Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/1471-2407-7-63 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.identifier.wosid | 000246354900001 | - |
dc.identifier.scopusid | 2-s2.0-34248177270 | - |
dc.citation.startpage | 63 | - |
dc.citation.volume | 7 | - |
dc.identifier.sci | 000246354900001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Chie, Eui Kyu | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Ha, Sung Whan | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | P53 | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | SENSITIVITY | - |
dc.subject.keywordPlus | SUPPRESSOR | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | DOCETAXEL | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.